Allergy
Therapeutics
plc
("Allergy Therapeutics" or "the Group")
Allergy Therapeutics presents
scientific advancements in its pollen and food-allergy research
portfolio at the 2025 AAAAI / WAO Joint Congress
27
February 2025 Allergy Therapeutics
plc (AIM: AGY), the integrated commercial biotechnology company
specialising in allergy immunotherapies, today announces that it
will be sharing key scientific findings from across its research
portfolio at the 2025 American Academy of
Allergy, Asthma & Immunology / World Allergy Organization
(AAAAI / WAO) Joint Congress,
taking place in San Diego, California from tomorrow, 28 February,
to 3 March 2025.
The 2025 AAAAI / WAO Joint Congress
is a premier conference in the field of allergy, asthma and
immunology, hosted by the American Academy of Allergy, Asthma &
Immunology (AAAAI), a leading membership organisation of more than
7,100 allergists/immunologists, and the World Allergy Organization
(WAO), an international umbrella
organisation whose members consist of 115 regional and national
allergology and clinical immunology societies. The congress brings
together thousands of clinicians, researchers and allied health
professionals from around the world who are dedicated to advancing
the understanding and treatment of allergic and immunologic
diseases.
Among its six posters being
presented, Allergy Therapeutics will share:
· A
positive comparative assessment highlighting the efficacy of the
pivotal Phase III trial with Grass MATA MPL, the Group's
short-course subcutaneous allergen-specific immunotherapy (SCIT)
candidate that aims to address the cause of symptoms of allergic
rhinoconjunctivitis due to grass pollen, against two regulatory
approved grass immunotherapy products
· Design
details of the G308 Phase III trial investigating the long-term
safety and efficacy of Grass MATA MPL in grass allergic children
and adolescents, which began in
November 2024
· Supporting safety and tolerability data from the ongoing Phase
I/IIa PROTECT clinical trial of the Group's novel
virus-like-particle (VLP)-based peanut allergy vaccine candidate
("VLP Peanut") in peanut allergic patients, which reported positive
interim biomarker efficacy data in
December 2024, demonstrating the
first evidence of the candidate's benign safety profile in peanut
allergic patients
Manuel Llobet, Chief Executive Officer at Allergy
Therapeutics, said: "We are
delighted to be showcasing our leading research at this year's
AAAAI / WAO Joint Congress, with six posters that highlight our
commitment to transforming patients' lives through innovative
therapies. Last year's submission of our marketing authorisation
application for Grass MATA MPL, the initiation of our G308 Phase
III trial in paediatric patients suffering from grass pollen
allergy and the positive interim data from our ongoing VLP Peanut
PROTECT trial, all illustrate the strength and pace of innovation
at Allergy Therapeutics. We look forward to sharing more about our
progress and learning from others at this important
congress."
The complete list of Allergy
Therapeutics-sponsored abstracts accepted by AAAAI / WAO for
presentation are available on the Group's website.
No new material price sensitive
information will be disclosed on Allergy Therapeutics at the 2025
AAAAI / WAO Joint Congress.
For further information, please
contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science
Specialist Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy
Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the
potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. For more information, please see www.allergytherapeutics.com.
